Details of Drug Interaction | MecDDI

Drug General Information (ID: DDIUO65VWM)
Drug Name			Eprosartan		Drug Info		Levodopa		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihypertensive Agents				Dopaminergic Antiparkinsonism Agents
Structure

Mechanism of Eprosartan-Levodopa Interaction (Severity Level: Moderate)
Additive hypotensive effects Click to Show/Hide Mechanism Graph

Drug Name		Eprosartan				Levodopa
Mechanism 1		Antihypertensive agent Angiotensin II receptor Antagonist				Antihypertensive agent
Key Mechanism Factor 1
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Eprosartan and Levodopa
Mechanism 2		Antihypertensive agent Angiotensin II receptor Antagonist				Hypotensive effects
Key Mechanism Factor 2
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Eprosartan and Levodopa

Recommended Action
Management		Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.

References
1	Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
2	Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8. [PMID: 11214778]
3	Product Information. Stalevo 150 (carbidopa/entacapone/levodopa). Novartis Pharmaceuticals, East Hanover, NJ.